• Report Adverse Event or Product Quality Complaint
  • Global Site
AstraZeneca Medical Information
  • Prescribing Information
  • Resources
    • Congress Library
    • Our Pipeline
    • AZ Clinical Trials
    • Externally Sponsored Scientific Research
  • Connect
    • Send MIR
    • Give Feedback

Search Medical Information

CHEST Annual Meeting 2024

October 06 - 09, 2024

  1. AIRSUPRA (albuterol/budesonide)
  2. BREZTRI (budesonide/glycopyrronium/formoterol)
  3. FASENRA (benralizumab)
  4. TEZSPIRE (tezepelumab)

PDF

Lessons from bench to bedside: Exploring genomic and non-genomic mechanisms of albuterol-budesonide as needed for treatment and prevention of acute airway obstruction (ALTA)

PDF

Severe Exacerbations in Patients Following Improved Adherence to Inhaled Corticosteroid-Containing Asthma Maintenance Medications Versus Not: A US Claim-Based Study

HTML

Efficacy of albuterol-budesonide rescue on top of inhaled corticosteroid/long-acting β-agonist (LABA) asthma maintenance therapy containing formoterol or other LABA (MANDALA)

HTML

Efficacy of albuterol-budesonide rescue in patients with moderate-to-severe asthma by smoking history (former vs never): Analysis of MANDALA

PDF

Perspectives on Clinical Discharge Protocols and the Initiation of Single-Inhaler Triple Therapy Following Severe COPD Exacerbations in the United States: An eDelphi Study

PDF

Reduced Risk of Cardiopulmonary Events for COPD Patients Initiating Budesonide/Glycopyrrolate/ Formoterol vs Multiple Inhaler Triple Therapy in the US: The SKOPOS-MAZI Study

PDF

Pulmonary and Cardiovascular Involvement and Persistent Damage in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Analysis of US Health Insurance Claims Data

PDF

Long-term remission and outcomes in patients with severe eosinophilic asthma (SEA) receiving benralizumab: MELTEMI post-hoc analysis

HTML

Efficacy of tezepelumab in patients with severe, uncontrolled asthma and allergic rhinitis grouped by baseline blood eosinophil count: pooled analysis of PATHWAY and NAVIGATOR

HTML

Effect of tezepelumab on patient-reported activity levels and sleep disturbance in patients with severe, uncontrolled asthma: results from the phase 3 NAVIGATOR study

HTML

Efficacy of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease by blood eosinophil count and smoking history: phase 2a COURSE study

Need Help?

Contact Us

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

AstraZeneca Logo

This platform is provided as service to healthcare professionals by AstraZeneca Philippines, for medical educational purposes only.

©2024 AstraZeneca. All rights reserved.

PH-10554.

Last Updated 5/24

Contact Us

About Us

AstraZeneca.com

Survey Feedback

Privacy Notice

Legal Notice

Cookie Notice

Global Site

Report Adverse Event or Product Quality Complaint

Privacy NoticeLegal NoticeCookie Notice

Welcome to AstraZeneca Philippines Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the Philippines, for medical educational purposes only. AstraZeneca does not engage in the promotion of unregistered products or unapproved indications. The dissemination of this information may be subject to different medical and regulatory requirements in other countries

Are you a healthcare professional practicing in the Philippines?

No